Polypodium leucotomos Extract for Melasma: Oral Photoprotection, Visible Light Defense, and What the Clinical Evidence Actually Shows (2026 Research Review)

Every brightening protocol eventually hits the same wall. The patient is compliant, the tyrosinase inhibitor is well formulated, the sunscreen is SPF 50+, and the melasma still relapses the moment real sun exposure resumes. That ceiling is why systemic photoprotection has moved from fringe curiosity to a legitimate research category — and Polypodium leucotomos extract is the most heavily studied agent in it.

This review examines what the molecular data show, what the human trials actually measured, why the visible-light findings matter more than the UVB findings for pigmentation, and where the evidence stops short of the marketing.

What Polypodium leucotomos Extract Actually Is

Polypodium leucotomos (also classified as Phlebodium aureum, family Polypodiaceae) is a fern native to Central and South America. The clinical material is a standardized hydrophilic leaf extract; the majority of published trials used the Fernblock standardization from Industrial Farmacéutica Cantabria, Madrid.

Activity is attributed to a dense phenolic fraction — ferulic, caffeic, chlorogenic, coumaric, vanillic and 3,4-dihydroxybenzoic acids. Formulators will recognize these as the same polyphenol families used topically for antioxidant defense. The distinction is the delivery route: systemic exposure rather than surface application.

Mechanism: Four Distinct Pillars

1. Reactive oxygen species scavenging

Parrado et al. (2016) describe inhibition of UV-induced ROS generation, downstream suppression of AP-1 and NF-κB signaling, and protection of endogenous antioxidant enzymes from depletion.

2. DNA damage reduction and accelerated repair

The strongest mechanistic dataset is Zattra et al. (2009) in American Journal of Pathology. Hairless Xpc(+/-) mice were fed the extract at 300 mg/kg for 10 days before a single UV exposure:

• Cyclobutane pyrimidine dimers: 31 ± 5% remaining at 72 hours versus 54 ± 5% in vehicle (p < 0.003)
• Oxidative DNA damage (8-OHdG-positive cells): down ~59% at 6 hours and ~79% at 24 hours; constitutive damage already ~36% lower before irradiation
• COX-2: four- to fivefold lower at 48 and 72 hours (p < 0.05)
• Inflammatory infiltrate: neutrophils down ~60% at 24 hours (p < 0.001), macrophages down ~50%
• UV-induced mutations: down ~25% at two weeks
• p53: expression and activity increased

This is the mechanistically important link for pigmentation. CPD formation and oxidative DNA damage are upstream drivers of the p53-dependent POMC and α-MSH cascade that instructs melanocytes to produce pigment. Reducing photochemical DNA damage does not inhibit tyrosinase — it reduces the signal that recruits tyrosinase in the first place.

3. Photoimmunoprotection

González et al. (1997) demonstrated preservation of CD1a-expressing epidermal Langerhans cells after solar irradiation, by both oral and topical routes. UV-induced Langerhans cell depletion is an established marker of local immunosuppression.

4. Extracellular matrix preservation

Parrado et al. also report prevention of UVA-induced mitochondrial DNA “common deletion” and inhibition of MMP-1 expression induced by visible light and infrared radiation — the wavelengths conventional sunscreens address least well.

Human Photoprotection Endpoints

In 21 healthy volunteers, González et al. found oral administration increased minimal erythema dose by a factor of 2.8 ± 0.59, and minimal phototoxic dose by 2.75 ± 0.5 to 6.8 ± 1.3-fold depending on the psoralen used. Kohli et al. (2017), studying 22 subjects with Fitzpatrick types I–III using a 308-nm excimer source, found reduced UVB-induced change in 17 of 22 subjects clinically and in all 22 histologically — though only two doses were administered.

The Visible Light Link — Why This Matters for Melasma

Mohammad et al. (2019) ran the study most relevant to pigmented skin. Twenty-two subjects with Fitzpatrick types IV–VI were irradiated with visible light, supplemented with 480 mg daily for 28 days, then re-irradiated (NCT02904798).

The authors attributed the non-significant IGA result to the insensitivity of visual scoring for small changes, which spectroscopy did detect. This is the core argument for systemic support: organic UV filters do not meaningfully attenuate visible light, yet visible light is a documented driver of pigmentation in darker phototypes. A systemic antioxidant is not filter-dependent — it acts wherever the photon deposits energy.

Melasma: What the Randomized Trials Show

The most applicable trial for Southeast Asian populations is Goh et al. (2018), conducted at the National Skin Centre in Singapore. Forty adults with melasma, all receiving topical 4% hydroquinone plus SPF 50+, were randomized to oral Polypodium leucotomos extract or placebo for 12 weeks.

• mMASI improved significantly from baseline in both groups at weeks 4, 8 and 12 (p ≤ 0.01)
• The treated group’s mMASI was significantly lower than placebo at weeks 8 and 12 (p ≤ 0.05)
• At study end, both groups had improved significantly, with no significant difference between them
• Melanin and erythema indices improved slightly in both groups, without significant separation
• MelasQoL scores favored the treated group; no significant adverse events

The authors’ framing is precise and worth repeating: the extract “significantly improves and accelerates” the outcome achieved with hydroquinone and sunscreen. Acceleration and quality of life — not a superior twelve-week endpoint. The study was sponsored by the ingredient supplier, which should be weighted accordingly.

Ahmed et al. (2013) published a randomized, double-blinded, placebo-controlled trial of the oral extract as a sunscreen adjunct in melasma in JAMA Dermatology, as a brief research letter. Subsequent reviews of systemic depigmenting therapy (Juhasz & Levin, 2018; Babbush et al., 2021) consistently characterize this evidence base as promising but preliminary.

What the Evidence Does Not Support

1. It is not a tyrosinase inhibitor. No credible depigmenting claim can be built on this mechanism.
2. The trials are small and short. Sample sizes of 20–40, durations of 12 weeks or less, several supplier-funded.
3. The between-group advantage did not persist to endpoint in Goh 2018. The honest read is faster onset and better patient-reported outcomes, not a better final result.
4. It is not a sunscreen replacement. Every positive trial layered supplementation on top of SPF 50+.

Product Development Implications

Dosing in the positive human studies clustered around 240 mg twice daily or 480 mg once daily; the vitiligo work by Middelkamp-Hup et al. (2007) used 250 mg three times daily alongside narrowband UVB. For topical development, González’s data showed photoprotection by that route as well — an aqueous phenolic extract of this type needs pH near 4.5–5.5, a chelator such as EDTA or sodium phytate, and opaque airless packaging, since polyphenols degrade under light and oxygen.

The coherent multi-pathway regimen: this extract addressing upstream oxidative and inflammatory load, a tyrosinase inhibitor addressing synthesis, niacinamide addressing melanosome transfer, and broad-spectrum sunscreen with iron oxides addressing the visible light fraction that filters miss. Claim substantiation should mirror the trial design that worked — adjunct-to-sunscreen, mMASI plus MelasQoL, twelve weeks.

Safety and Regulatory Notes

Oral tolerability was good across the cited trials. Topically, Polypodium Leucotomos Leaf Extract is an accepted cosmetic ingredient under EU Regulation (EC) No 1223/2009 and is workable within ASEAN frameworks. Oral formats fall under separate supplement regimes that differ materially by market — Singapore HSA, Thailand FDA and Indonesia BPOM each treat ingestible claims differently. The two routes are not interchangeable for registration purposes.

Summary

Polypodium leucotomos extract is the best-evidenced systemic photoprotective agent available, with a genuinely distinctive mechanism: it reduces DNA photodamage and inflammatory signaling upstream of melanogenesis rather than inhibiting the pigment pathway itself. Its most compelling pigmentation data is not the UVB work but the visible-light study in Fitzpatrick IV–VI skin — precisely the exposure conventional filters handle worst.

The realistic positioning is an adjunct that accelerates response and improves quality of life on top of a competent topical and photoprotection regimen. That is defensible and evidence-aligned. Anything stronger outruns the data.

References

1. Goh CL, Chuah SY, Tien S, Thng G, Vitale MA, Delgado-Rubin A. Double-blind, placebo-controlled trial to evaluate the effectiveness of Polypodium leucotomos extract in the treatment of melasma in Asian skin: a pilot study. J Clin Aesthet Dermatol. 2018;11(3):14-19. PMID: 29606995.
2. Mohammad TF, Kohli I, Nicholson CL, et al. Oral Polypodium leucotomos extract and its impact on visible light-induced pigmentation in human subjects. J Drugs Dermatol. 2019;18(12):1198-1203. PMID: 31859468.
3. Zattra E, Coleman C, Arad S, et al. Polypodium leucotomos extract decreases UV-induced Cox-2 expression and inflammation, enhances DNA repair, and decreases mutagenesis in hairless mice. Am J Pathol. 2009;175(5):1952-1961. PMID: 19808641.
4. Kohli I, Shafi R, Isedeh P, et al. The impact of oral Polypodium leucotomos extract on ultraviolet B response: a human clinical study. J Am Acad Dermatol. 2017;77(1):33-41.e1. PMID: 28341348.
5. González S, Pathak MA, Cuevas J, Villarrubia VG, Fitzpatrick TB. Topical or oral administration with an extract of Polypodium leucotomos prevents acute sunburn and psoralen-induced phototoxic reactions as well as depletion of Langerhans cells in human skin. Photodermatol Photoimmunol Photomed. 1997;13(1-2):50-60. PMID: 9361129.
6. Parrado C, Mascaraque M, Gilaberte Y, Juarranz A, Gonzalez S. Fernblock (Polypodium leucotomos extract): molecular mechanisms and pleiotropic effects in light-related skin conditions, photoaging and skin cancers, a review. Int J Mol Sci. 2016;17(7):1026. PMID: 27367679.
7. Ahmed AM, Lopez I, Perese F, et al. A randomized, double-blinded, placebo-controlled trial of oral Polypodium leucotomos extract as an adjunct to sunscreen in the treatment of melasma. JAMA Dermatol. 2013;149(8):981-983. PMID: 23740292.
8. Middelkamp-Hup MA, Bos JD, Rius-Diaz F, Gonzalez S, Westerhof W. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J Eur Acad Dermatol Venereol. 2007;21(7):942-950. PMID: 17659004.
9. Juhasz MLW, Levin MK. The role of systemic treatments for skin lightening. J Cosmet Dermatol. 2018;17(6):1144-1157. PMID: 30133125.
10. Babbush KM, Babbush RA, Khachemoune A. Treatment of melasma: a review of less commonly used antioxidants. Int J Dermatol. 2021;60(2):166-173. PMID: 32815582.